SecBot SecBot
PRESS-RELEASE ·Filed Mar 30, 2026

NRXP

NRx Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

This partnership enhances NRXP's care delivery model with a scalable, data-driven tool that could improve clinical outcomes and differentiate its clinic network. Traders should monitor for future monetization pathways, such as licensing the platform or bundling it with treatments. Watch for upcoming clinical trial results validating real-world efficacy.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.09
T+0 close · Mar 30, 2026 · via day close
Latest settled
+70.33%
T+60 · $3.56
Vs SPY
+53.84%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $2.09entry
  2. T+1 · 8mo ago +1.91%α −0.98% · $2.13
  3. T+5 · 7mo ago +6.70%α +2.40% · $2.23
  4. T+20 · 7mo ago +41.15%α +28.55% · $2.95
  5. T+60 · 5mo ago +70.33%α +53.84% · $3.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals' subsidiary Hope Therapeutics partnered with Emobot Health to deploy an AI-powered 'Depression Thermometer' across its interventional psychiatry clinics. The technology enables passive, real-time monitoring of depression and anxiety via smartphone, aiming to reduce relapse rates and improve patient outcomes through early intervention.

Key Facts

  • Hope Therapeutics (NRXP subsidiary) partnered with Emobot Health to integrate AI-driven emotional monitoring in its clinic network.
  • Emobot's 'Depression Thermometer' passively analyzes facial expressions, vocal tones, and actigraphy to detect early relapse in TRD patients.
  • Clinical validation shows strong correlation with MADRS (r=0.89) and PHQ-9 (r=0.83) scales.
  • The platform aims to double patient success rates by enabling timely recapture interventions like maintenance ketamine or TMS.
  • Patients receive real-time mood insights and can reschedule appointments in-app upon relapse detection.

Financial Impact

No direct financial figures disclosed; potential long-term revenue upside from improved patient retention and expanded digital health offering.

revenuepatient retentionoperational efficiency

Risk Factors

  • No immediate revenue impact; commercial benefits are forward-looking and dependent on adoption and clinical outcomes.
  • Regulatory scrutiny may arise if the AI platform is deemed a medical device requiring FDA clearance.
  • Forward-looking statements dominate the release, actual performance may not match expectations.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3264474

Track record

22 reports on NRXP

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +38.36% at T+5 after the May 18, 2026 report. 9 of 12 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 30, 2026